相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Protara's TARA-002 cell therapy demonstrated a 72% complete response rate in BCG-naïve non-muscle invasive bladder cancer patients during the Phase II ADVANCED-2 trial. - The therapy maintained durable responses with 69% complete response at six months and 50% at 12 months, while showing favorable tolerability with mostly Grade 1 adverse events. - If approved, TARA-002 would become the first drug to receive regulatory approval for BCG-naïve NMIBC since BCG itself was introduced decades ago. - Protara's stock increased 9% following the announcement, and analysts forecast the drug could generate $62 million in its first year and $452 million by 2031.
- enGene's detalimogene voraplasmid demonstrated a 63% complete response rate at three months in high-risk, BCG-unresponsive non-muscle invasive bladder cancer patients in the pivotal LEGEND Phase II trial. - The complete response rate improved from 56% at three months to 62% at six months, with all five patients completing nine-month assessments maintaining complete response. - The gene therapy showed favorable safety profile with 42% of patients experiencing treatment-related adverse events, mostly Grade 1/2 severity, supporting planned BLA submission in H2 2026.
- The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to detalimogene voraplasmid for treating high-risk BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. - Preliminary data from the pivotal LEGEND trial showed a 71% overall complete response rate in 21 evaluable patients, with a favorable safety profile. - The RMAT designation provides regulatory advantages including expedited development, intensive FDA guidance, and potential for rolling or priority review. - Detalimogene is a non-viral gene-based immunotherapy designed for bladder instillation to elicit localized anti-tumor immune responses.
- enGene's detalimogene voraplasmid demonstrates a 71% complete response rate in patients with BCG-unresponsive NMIBC with CIS in the LEGEND study. - The LEGEND study protocol has been amended to align with current treatment standards and real-world practices, potentially improving patient outcomes. - enGene's existing cash reserves of $297.9 million are expected to fund operations into 2027, supporting the advancement of detalimogene. - The BLA filing for detalimogene in BCG-unresponsive NMIBC with CIS is on track for mid-2026, marking a significant step toward potential market approval.
